Paper Details

  1. Home
  2. Paper Details

Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis.

Author: AddeoPietro, BachellierPhilippe, BaharyNathan, BaliMaria A, Bekaii-SaabTanios, BesselinkMarc G, BeumerBerend R, BooneBrian A, BuettnerStefan, ChauIan, ClarkeStephen, DillhoffMary, El-RayesBassel F, FrakesJessica M, Groot KoerkampBas, GroseDerek, HomsMarjolein Y V, HoseinPeter J, JamiesonNigel B, JanssenQuisette P, JavedAmmar A, KatzMatthew H G, KhanKhurum, KimKyu-Pyo, KimSong Cheol, KimSunhee S, KoAndrew H, LacyJill, MargonisGeorgios A, McCarterMartin D, McKayColin J, MellonEric A, MoorcraftSing Yu, OkadaKen-Ichi, PanicciaAlessandro, ParikhParag J, PetersNiek A, RablHans, SamraJaswinder, SukerMustafa, TinchonChristoph, Wang-GillamAndrea, WeissMatthew J, WilminkJohanna W, YamaueHiroki, van EijckCasper H J, van TienhovenGeertjan, van VeldhuisenEran

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Neoadjuvant FOLFIRINOX showed a favorable median OS, resection rate, and R0-resection rate in BRPC patients.
Paper Details　
Original Abstract of the Article :
BACKGROUND: FOLFIRINOX is a standard treatment for metastatic pancreatic cancer patients. The effectiveness of neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer (BRPC) remains debated. METHODS: We performed a systematic review and patient-level meta-analysis on neoadju...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6695305/

データ提供：米国国立医学図書館（NLM）

FOLFIRINOX: A Powerful Tool for Treating Borderline Resectable Pancreatic Cancer

Pancreatic cancer is a challenging disease, and this study investigates the effectiveness of neoadjuvant FOLFIRINOX in treating borderline resectable pancreatic cancer (BRPC). Imagine a desert oasis, where a tumor, like a encroaching sand dune, threatens the delicate balance of the oasis. This study explores the potential of FOLFIRINOX, like a powerful desert storm, to shrink the tumor, making it amenable to surgery. The researchers conducted a systematic review and patient-level meta-analysis to evaluate the efficacy of FOLFIRINOX in treating BRPC.

FOLFIRINOX: A Potential Game Changer for BRPC

The study found that FOLFIRINOX, like a skilled desert sculptor, effectively shrank tumors, leading to a significant resection rate and R0-resection rate. The findings suggest that FOLFIRINOX could be a valuable tool for treating BRPC, potentially improving patient survival and quality of life. The research underscores the potential of FOLFIRINOX as a promising neoadjuvant therapy for BRPC.

Pancreatic Cancer: Seeking Effective Treatments

This study emphasizes the importance of seeking prompt and effective treatment for pancreatic cancer. It highlights the potential of FOLFIRINOX as a promising treatment option, potentially improving patient outcomes. The study encourages further research to evaluate the long-term benefits of FOLFIRINOX, potentially leading to even more effective treatment strategies for pancreatic cancer.

Dr.Camel's Conclusion

The study highlights the potential of FOLFIRINOX as a powerful tool for treating borderline resectable pancreatic cancer, offering hope for a future where this challenging disease is more effectively managed. The findings suggest that FOLFIRINOX could significantly improve patient survival and quality of life. Further research is needed to fully understand the long-term benefits of FOLFIRINOX, but this study offers a glimmer of hope for patients battling pancreatic cancer.

Date :
  1. Date Completed 2020-06-09
  2. Date Revised 2021-03-12
Further Info :

Pubmed ID

31086963

DOI: Digital Object Identifier

PMC6695305

Related Literature

Article Analysis
・Effective treatment of pancreatic cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.